Yahoo · Oct 9, 2026
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
NASDAQ · GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$151.17
Up+$4.07 (+2.77%)
Updated Oct 10, 2026, 10:27 PM
SID Score
7.5/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 152.89B
- P/E ratio
- 18.89
- Dividend yield
- 2.60%
- 52-week range
- $116.88 – $157.29
- Volume
- 5.8M
- Avg. volume
- 7.34M
Price performance · GILD
GILD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
GILD closed at $151.17 after 21 trading sessions, up 5.18% for the selected period.
- Last close
- $151.17
- Period change
- +5.18%
- Period low
- $143.72
- Period high
- $152.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $147.23 | $151.44 | $146.10 | $151.17 | 5.8M |
| Oct 8, 2026 | $146.73 | $147.59 | $144.65 | $147.10 | 4.49M |
| Oct 7, 2026 | $145.275 | $148.60 | $144.85 | $146.85 | 5.1M |
| Oct 6, 2026 | $145.11 | $146.14 | $142.5982 | $144.23 | 3.72M |
| Oct 5, 2026 | $143.21 | $145.16 | $142.79 | $144.63 | 6.14M |
| Oct 2, 2026 | $147.65 | $148.00 | $144.00 | $144.74 | 5.04M |
| Oct 1, 2026 | $149.44 | $149.44 | $147.185 | $147.50 | 4.44M |
| Sep 30, 2026 | $150.875 | $151.28 | $148.98 | $149.05 | 5.36M |
| Sep 29, 2026 | $150.18 | $152.625 | $148.785 | $151.28 | 5.32M |
| Sep 28, 2026 | $149.795 | $152.74 | $149.41 | $152.21 | 5.08M |
| Sep 25, 2026 | $150.05 | $151.00 | $148.02 | $150.93 | 5.28M |
| Sep 24, 2026 | $151.10 | $152.975 | $149.59 | $149.69 | 5.08M |
| Sep 23, 2026 | $153.60 | $154.1999 | $150.06 | $151.37 | 6.19M |
| Sep 22, 2026 | $150.645 | $153.2807 | $148.65 | $152.67 | 5.08M |
| Sep 21, 2026 | $150.11 | $152.095 | $148.22 | $150.56 | 5.57M |
| Sep 18, 2026 | $150.56 | $153.23 | $149.57 | $150.11 | 16.42M |
| Sep 17, 2026 | $148.775 | $151.04 | $146.8901 | $150.89 | 7.84M |
| Sep 16, 2026 | $146.58 | $149.30 | $146.12 | $147.68 | 5.19M |
| Sep 15, 2026 | $144.002 | $146.35 | $142.94 | $146.30 | 4.54M |
| Sep 14, 2026 | $144.26 | $146.75 | $143.71 | $146.41 | 4.92M |
| Sep 11, 2026 | $145.24 | $145.99 | $143.50 | $143.72 | 4.2M |
Latest GILD news
The latest Smart Investors Daily articles mentioning GILD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GILD research
Overview
Company profile and research snapshot.
Company profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $130.64
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 8, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 7, 2026 | JP Morgan | Overweight | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Oct 7, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.
Yahoo · Oct 8, 2026
What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?
Cognizant Technology Solutions (NasdaqGS: CTSH) announced multi-year AI-focused partnerships with Gilead Sciences and SITA. The Gilead agreement targets AI-enabled DevOps and finance transformation programs using Cognizant's cloud and automation capabilities. The SITA collaboration focuses on applying Cognizant's AI tools across global air transport technology systems and related services. Cognizant also introduced Cognizant Activate, a program aimed at speeding AI adoption for emerging...
Benzinga · Oct 8, 2026
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
